Avid Bioservices Inc (CDMO)

[dia76ca]

Entdoc, I like your idea to go it alone as long as possible. That may indeed be a very short time in the antiviral sphere. Here is what Affi said about the human versions of Bavi.
___________________________________________

• AT004 and AT005 – AT004 and AT005 are currently in preclinical research. We are collaborating with Peregrine Pharmaceuticals in developing these fully human antibodies which we discovered, that are targeted against Phosphatidylserine, a phospholipid exposed on the surface of viral infected cells and certain cancer cells. Peregrine Pharmaceuticals has recently reported that bavituximab, a chimeric antibody against the same target, has shown initial evidence of efficacy in Phase II studies in lung cancer and breast cancer. Our antibodies are improved second-generation human versions of bavituximab.

_____________________________________________

And from the last CC we heard that under the DTRA contract they are evaluating "Bavi and a similar HUMAN ANTIBODY as potential broad-spectrum treatments or preventatives for hemorrhagic fever".

We also heard that in regard to Duke/Haynes that the article is in the process of being published...but that they have moved "beyond that research". "In fact we're expanding our collaboration with them, looking at many different areas, A NUMBER OF DIFFERENT ANTIBODIES...so this first publication is only the beggining of what we expect to be a a really fruitful long-term relationship".

It may not be long before the DTRA and Duke/Haynes humanized antivirals are in the clinic!